Mirikizumab for Healthy Subjects

This trial tests the safety of a drug called mirikizumab (an antibody therapy) when administered as a single injection versus two injections under the skin. Researchers aim to observe how the body processes the drug by checking blood tests. The trial seeks healthy individuals without major health issues or allergies to similar medications. Participants will not need to take any other medications during the study. The trial lasts about 15 weeks. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

Yes, you will need to stop taking any over-the-counter or prescription medications, including herbal and traditional medications, at least 7 days before starting the trial.

Research has shown that mirikizumab has been tested in earlier studies to ensure its safety for humans. Serious infections occurred in less than 1% of patients, with some cases being severe, such as intestinal infections and listeria sepsis. Another study found that mirikizumab can cause serious allergic reactions, including anaphylaxis, which requires immediate medical attention.

Mirikizumab is unique because it targets interleukin-23 (IL-23), a protein involved in inflammation, and is administered subcutaneously. This is different from many current treatments for conditions like psoriasis or inflammatory bowel diseases, which might target other pathways or require intravenous administration. Researchers are excited about mirikizumab because its targeted approach could offer more precise control of inflammation with potentially fewer side effects. Additionally, the convenience of subcutaneous administration could improve patient compliance and overall treatment experience.

Research has shown that mirikizumab can help treat certain inflammatory conditions. For people with ulcerative colitis, studies have found that more than half of the patients experienced no symptoms after a year of treatment. Another study showed that mirikizumab worked better than a placebo, helping patients achieve and maintain symptom relief. In patients with Crohn's disease, long-term use of mirikizumab kept over 90% of those in remission free of symptoms. These findings suggest that mirikizumab could be a promising option for managing these conditions.⁶⁷⁸⁹¹⁰